

P&T Motion History Antiemetics

Drugs reviewed	Motion	Date reviewed	Scan accepted as adequate	Reiteration of prior motion	Decision
aprepitant/fosaprepitant dolasetron doxylamine /pyridoxine granisetron <ul style="list-style-type: none"> • oral tablet • IV solution • Sancuso (transdermal patch) • Sustol (SQ prefilled syringe) netupitant/palonosetron ondansetron <ul style="list-style-type: none"> • IV solution • oral solution • ODT • oral tablet • Zuplenz (oral film) palonosetron rolapitant	<p>After considering the evidence of safety, efficacy and special populations I move that aprepitant, doxylamine /pyridoxine, netupitant/palonosetron, fosaprepitant, granisetron, ondansetron, rolapitant, dolasetron, and palonosetron are efficacious for their FDA approved indications. The preferred drug list must include at least one medication that includes alternate routes approved in both adults and children. The antiemetics can be subject to therapeutic interchange within their mechanism of action in the Washington preferred drug list. The preferred drug list must include a neuro kinin 1 antagonist for patients receiving highly emetogenic chemotherapy and/or radiation therapy.</p> <p>Request for more information on the harms of rolapitant.</p> <p>Motion: Figueroa 2nd: Chew</p>	August 15, 2018	Yes Sanderson Schwilke	No	Passed unanimous

BOLD = new this review

8/16/2018